Novelos Claims Securities Action Strikes Out

Law360, New York (September 12, 2011, 3:26 PM EDT) -- Novelos Therapeutics Inc. argued Friday that a putative class of investors alleging the company misled them about the prospects of a developmental-stage cancer drug had failed for a third time to state a claim, and thus the complaint should be dismissed for good.

In a motion to dismiss filed in Boston federal court, Novelos said that new claims in a second amended complaint filed in August alleging that the company changed the formula of lung cancer drug NOV-002 in 2005 without approval from the U.S. Food...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Urman, et al v. Novelos Therapeutics, Inc. et al


Case Number

1:10-cv-10394

Court

Massachusetts

Nature of Suit

Securities/Commodities

Judge

Nathaniel M. Gorton

Date Filed

March 5, 2010

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.